Research on lurbinectedin and pregnancy is limited. Lurbinectedin is a medication primarily used in the treatment of certain types of cancer. The drug is not recommended for use during pregnancy as it may cause harm to the fetus. Clinical trials involving lurbinectedin, such as NCI-2023-04827 and Dana-Farber 21-437, do not typically include pregnant women due to the potential risks to both the mother and the unborn child. It is crucial for women of childbearing potential to use effective contraception while receiving treatment with lurbinectedin to prevent pregnancy-related complications. For more information on the safety and potential risks of lurbinectedin during pregnancy, consulting with a healthcare provider or clinical trial investigator is recommended.

Sources:
[1] drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] cancer.gov/clinicaltrials/NCI-2023-04827
[3] dana-farber.org/clinical-trials/21-437